Use of zcytor17 ligand antagonists for treating inflammatory diseases
AssigneeZymoGenetics, Inc.
InventorsCindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond
Life of this patent
Estimating the term…
Abstract
The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
Claims24
A method of treating an inflammatory disease in a mammal comprising administering to the mammal a therapeutically effective amount of an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2, wherein the inflammatory disease is selected from the group consisting of atopic dermatitis, inflammatory bowel disease, ulcerative colitis, Crohn's disease and eczema.
A method of treating an inflammatory disease in a mammal comprising administering to the mammal a therapeutically effective amount of a composition comprising an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2, and a pharmaceutically acceptable carrier, wherein the inflammatory disease is selected from the group consisting of atopic dermatitis, inflammatory bowel disease, ulcerative colitis, Crohn's disease and eczema.
Dependencies are inferred from the claim text.